作者
John JV McMurray, David L DeMets, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna M Langkilde, Felipe A Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, DAPA‐HF Committees and Investigators, John JV McMurray, David L DeMets, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, Mirta Diez, Jose Nicolau, Tzvetana Katova, Eileen O'Meara, Jonathan Howlett, Subodh Verma, Junbo Ge, Jan Belohlavek, Morten Schou, Michael Böhm, Bela Merkely, Vijay Chopra, Masafumi Kitakaze, Rudolf A de Boer, Jaroslaw Drozdz, Sergey Tereshchenko, Andrej Dukat, Charlotta Ljungman, Chern‐En Chiang, Mark Petrie, Akshay Desai, Inder Anand, Vinh Nguyen Pham, Marc A Pfeffer, Stuart Pocock, Karl Swedberg, Jean L Rouleau, Nishi Chaturvedi, Peter Ivanovich, Andrew S Levey, Heidi Christ‐Schmidt, Claes Held, Christoph Varenhorst, Christina Christersson, Johannes Mann, Pernilla Holmgren, Theresa Hallberg, AnnaMaria Langkilde, Mikaela Sjöstrand, Hans Denison, Barry Reicher, Olof Bengtsson, Ywonne Fox, Mikael Forsby, Eva‐Lena Alenhag, Ann Nilsson, Kinga Kazanowska, Eva Lavik Olofsson, Cathrine Karup, Maria Ekedahl‐Berggren, Anna‐Lena Klockargård, Karin Kempe, Mathilda Selvén
发表日期
2019/5
期刊
European journal of heart failure
卷号
21
期号
5
页码范围
665-675
出版商
John Wiley & Sons, Ltd
简介
Background
Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseline and the effect of SGLT2 inhibitors on outcomes in individuals with established heart failure (with or without diabetes) is unknown.
Design and methods
The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure trial (DAPA‐HF) is an international, multicentre, parallel group, randomized, double‐blind, study in patients with chronic heart failure, evaluating the effect of dapagliflozin 10 mg, compared with placebo, given once daily, in addition to standard care, on the primary composite outcome of a worsening heart failure event (hospitalization or equivalent event, i.e. an urgent heart failure visit) or …
学术搜索中的文章
JJV McMurray, DL DeMets, SE Inzucchi, L Køber… - European journal of heart failure, 2019